(Q33497526)

27 July 2017

Side effects of high-dose interferon therapy for chronic hepatitis C. (English)

1 reference

27 July 2017

1 reference

Okanoue T

1

1 reference

27 July 2017

Sakamoto S

2

1 reference

27 July 2017

Itoh Y

3

1 reference

27 July 2017

Minami M

4

1 reference

27 July 2017

Yasui K

5

1 reference

27 July 2017

Sakamoto M

6

1 reference

27 July 2017

Nishioji K

7

1 reference

27 July 2017

Katagishi T

8

1 reference

27 July 2017

Nakagawa Y

9

1 reference

27 July 2017

Tada H

10

1 reference

27 July 2017

Sawa Y

11

1 reference

27 July 2017

Mizuno M

12

1 reference

27 July 2017

Kagawa K

13

1 reference

27 July 2017

Kashima K

14

1 reference

27 July 2017

1 September 1996

1 reference

27 July 2017

Journal of Hepatology

1 reference

27 July 2017

25

1 reference

27 July 2017

283-291

1 reference

27 July 2017

3

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

27 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Psychiatric complications of long-term interferon alfa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Clinical toxicity of the interferons.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Latent autoimmune thyroid disease in patients with chronic HCV hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Interferon-induced chronic active hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Immune thrombocytopenia following alpha-interferon therapy in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Alpha-interferon and immune hemolytic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Interferon-associated retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

Sudden hearing loss associated with interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980113-9

7 January 2021

10.1016/S0168-8278(96)80113-9

Identifiers

DOI

1 reference

release_r6tsfefmsve4dgxm77efrmomtm

27 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r6tsfefmsve4dgxm77efrmomtm

24 November 2022

mapped directly with Wikidata item

1 reference